The advent of highly active antiretroviral therapy has resulted in a decline in the incidence of opportunistic infections and prolonged survival in HIV-1 infected individuals. Obstacles towards virus erradication include the continued presence of an infected quiescent pool, drug resistance, toxicities, and lack of treatment adherence. The goal of genetic therapies is the replacement of the HIV-1-infected cell reservoir with cells that have been genetically engineered to resist HIV-1 replication. Unlike conventional drugs, it is possible to create a """"""""single administration"""""""" reagent. However, successful gene therapy strategies require efficient gene delivery into hematopoietic stem cells and the presence and expression of the anti HIV genes in differentiated progenies that persist for years if not for the life of the individual. Thus, these current limitations must be investigated. A better understanding of the limitations of gene therapy techniques can lead to strategies to overcome such limitations as well as design potential clinical scenarios in which to test them. As possible alternatives or complements to antiretroviral therapy, stem cell gene therapy strategies are of interest to the scientific community, to the health policy community in particular and to the public at large. The overall goal of the Gene and Cellular Therapy Core (Core G) is to provide scientific and technical support for basic laboratory and clinical trial projects that require the use of purified CD34+ hematopoietic stem cells for HIV/AIDS gene therapy, hematopoiesis and pathogenesis of HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI028697-21
Application #
8048155
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
21
Fiscal Year
2010
Total Cost
$75,691
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Allan-Blitz, Lao-Tzu; Sakona, Ashyln; Wallace, William D et al. (2018) Coxiella burnetii Endocarditis and Meningitis, California, USA, 2017. Emerg Infect Dis 24:
Rotheram-Borus, Mary Jane; Davis, Emily; Rezai, Roxana (2018) Stopping the rise of HIV among adolescents globally. Curr Opin Pediatr 30:131-136
Kojima, Noah; Klausner, Jeffrey D (2018) An Update on the Global Epidemiology of Syphilis. Curr Epidemiol Rep 5:24-38
Nakatsuka, Nako; Hasani-Sadrabadi, Mohammad Mahdi; Cheung, Kevin M et al. (2018) Polyserotonin Nanoparticles as Multifunctional Materials for Biomedical Applications. ACS Nano 12:4761-4774
Cisneros, Irma E; Erdenizmenli, Mert; Cunningham, Kathryn A et al. (2018) Cocaine evokes a profile of oxidative stress and impacts innate antiviral response pathways in astrocytes. Neuropharmacology 135:431-443
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
Yu, Jingyi; Seldin, Marcus M; Fu, Kai et al. (2018) Topological Arrangement of Cardiac Fibroblasts Regulates Cellular Plasticity. Circ Res 123:73-85
de la Torre-Ubieta, Luis; Stein, Jason L; Won, Hyejung et al. (2018) The Dynamic Landscape of Open Chromatin during Human Cortical Neurogenesis. Cell 172:289-304.e18
Epeldegui, Marta; Magpantay, Larry; Guo, Yu et al. (2018) A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma. AIDS 32:945-954
Kiertscher, Sylvia M; Gangalum, Pallavi R; Ibrahim, Grace et al. (2018) A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol 13:219-229

Showing the most recent 10 out of 942 publications